Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Recruiting now · Not applicable

Conditions studied: Obesity

In brief

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Key facts

Study ID

NCT06278285

Run by

Centre Hospitalier Universitaire de Nice

People needed

40

Starts

2024-03-06

Expected to finish

2027-03-06

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient over 18 years of age.
• Patient able to read and understand the information/consent leaflet.
• Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
• Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
• Membership of a social security scheme
• Patient's signed informed consent
• For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
• For non-GLP-1 analogue group: never taken GLP-1 analogues.

You may not qualify if…

• Pregnant or breast-feeding women.
• Vulnerable patients (under guardianship)
• Patients deprived of liberty

Where it is running

• CHU de Nice - Hôpital de l'Archet — Nice, Alpes-maritimes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.